Trinity Biotech Warned by Nasdaq for Non-Compliance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy TRIB?
Trinity Biotech received notice from Nasdaq that the company no longer meets the requirement in Nasdaq Listing Rule 5450 that listed securities maintain a minimum market value of publicly held shares of $15M, based on Nasdaq's review of the company's MVPHS for the last 30 consecutive business days.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRIB
About TRIB
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trinity Biotech Enters $25 Million Equity Purchase Agreement
- Financing Agreement Details: Trinity Biotech has entered into a $25 million standby equity purchase agreement with an affiliate of Yorkville Advisors Global, allowing the company to sell newly issued American Depositary Shares over a 36-month period, aimed at supporting its commercialization and R&D initiatives.
- Pricing Mechanism: Under the agreement, shares issued will be priced at either 97% of the lowest daily volume-weighted average price during a three-day pricing period or 95% of the VWAP during a single-day pricing period, providing the company with flexible financing options to potentially lower costs.
- Market Reaction: Following the announcement of the agreement, Trinity Biotech's shares dipped slightly to $0.75 in pre-market trading, reflecting a cautious market sentiment regarding the financing arrangement while highlighting investor interest in the company's future prospects.
- Strategic Implications: This financing agreement not only provides essential funding for Trinity Biotech but also supports its commercialization efforts in areas such as HIV testing, further solidifying its market position in the biotechnology sector.
See More
Trinity Biotech PLC Secures $25 Million SEPA with Yorkville Advisors Global Affiliate
Investment Announcement: Trinity Biotech PLC has entered into a $25 million SEPA with an affiliate of Yorkville Advisors.
Financial Partnership: The agreement involves a financing partnership aimed at supporting Trinity Biotech's growth and operational needs.
See More
Trinity Biotech Faces Nasdaq Compliance Issue
- Compliance Notice: On February 19, 2026, Trinity Biotech received a notice indicating it no longer meets Nasdaq's minimum public float requirement of $15 million, which poses a risk to its continued listing on the exchange.
- Market Reaction: Despite the compliance issue, Trinity Biotech's stock price rose due to an order for 9 million TrinScreen HIV tests, reflecting market confidence in product demand and potentially alleviating investor concerns regarding compliance deficiencies.
- Rating Dynamics: Seeking Alpha's Quant Rating on Trinity Biotech reveals mixed market sentiment about its future performance; while compliance issues persist, the increase in orders may influence investor perceptions positively.
- Financial Disclosure: Financial information from Trinity Biotech indicates its market performance; despite compliance challenges, the expansion of its product line and growth in orders may provide financial support to help navigate current compliance pressures.
See More
Trinity Biotech Receives Regulatory Approval for New Production Model Launch
- Regulatory Milestone: Trinity Biotech has received local regulatory approval, marking the initiation of upstream manufacturing activities for its Uni-Gold™ HIV rapid test under a new outsourced production model, which is a key component of the company's comprehensive transformation plan.
- Cost Efficiency Improvement: The implementation of the offshore and outsourced production model is expected to significantly enhance gross margins and improve working capital efficiency, thereby strengthening the company's long-term competitiveness in the global HIV rapid testing market.
- Market Demand Support: This transition will not only meet the anticipated growth in demand for Uni-Gold™ HIV products but also provide the necessary scalability to ensure the company remains agile and responsive in a rapidly changing market environment.
- Strategic Transformation Plan: This approval complements the WHO authorization obtained in November 2025, demonstrating the company's strong commitment to executing its comprehensive transformation plan, which is expected to lay a solid foundation for future financial performance.
See More
Indaptus Therapeutics Stock Soars 64.65% to $3.26 After Securities Agreement
- Significant Stock Movement: Indaptus Therapeutics saw its stock decline 2.46% to $1.98 at close but surged 64.65% to $3.26 in after-hours trading, indicating strong investor confidence in its future potential.
- Financing Agreement: The company entered into a securities purchase agreement with investor David E. Lazar on December 22, 2025, selling 1 million shares of convertible preferred stock for $6 million, which is expected to provide financial support pending shareholder approval.
- Positive Market Reaction: Trinity Biotech's stock surged 43.50% to $1.28 after announcing a significant HIV testing order, reflecting market optimism regarding its financial stability and demand recovery.
- Pipeline Restart Approval: Sable Offshore's shares rose 36.32% to $10.36 following the U.S. Pipeline and Hazardous Materials Safety Administration's approval of the Las Flores Pipeline system restart plan, marking a critical step forward in the company's operational recovery.
See More
Dow Jones Index Gains Over 100 Points as Durable Goods Orders Decline 2.2%
- Dow Jones Index Rise: The Dow Jones index increased by over 100 points on Tuesday, closing at 48,469.41, indicating a moderate market recovery despite disappointing economic data.
- Durable Goods Orders Decline: U.S. durable goods orders fell by 2.2% month-over-month to $307.4 billion in October, significantly missing market expectations of a 1.5% decline, reflecting weak manufacturing demand that could impact future economic growth.
- Accelerated GDP Growth: The U.S. GDP grew at an annualized rate of 4.3% in the third quarter, up from 3.8% in the previous quarter and exceeding market estimates of 3.3%, indicating potential for economic recovery that may positively influence the stock market.
- Mixed Sector Performance: Communication services rose by 0.5% while consumer staples fell by 0.5%, demonstrating varied market reactions across sectors, prompting investors to monitor industry dynamics for strategic adjustments.
See More
Trinity Biotech Enters $25 Million Equity Purchase Agreement
- Financing Agreement Details: Trinity Biotech has entered into a $25 million standby equity purchase agreement with an affiliate of Yorkville Advisors Global, allowing the company to sell newly issued American Depositary Shares over a 36-month period, aimed at supporting its commercialization and R&D initiatives.
- Pricing Mechanism: Under the agreement, shares issued will be priced at either 97% of the lowest daily volume-weighted average price during a three-day pricing period or 95% of the VWAP during a single-day pricing period, providing the company with flexible financing options to potentially lower costs.
- Market Reaction: Following the announcement of the agreement, Trinity Biotech's shares dipped slightly to $0.75 in pre-market trading, reflecting a cautious market sentiment regarding the financing arrangement while highlighting investor interest in the company's future prospects.
- Strategic Implications: This financing agreement not only provides essential funding for Trinity Biotech but also supports its commercialization efforts in areas such as HIV testing, further solidifying its market position in the biotechnology sector.
See More
Trinity Biotech PLC Secures $25 Million SEPA with Yorkville Advisors Global Affiliate
Investment Announcement: Trinity Biotech PLC has entered into a $25 million SEPA with an affiliate of Yorkville Advisors.
Financial Partnership: The agreement involves a financing partnership aimed at supporting Trinity Biotech's growth and operational needs.
See More
Trinity Biotech Faces Nasdaq Compliance Issue
- Compliance Notice: On February 19, 2026, Trinity Biotech received a notice indicating it no longer meets Nasdaq's minimum public float requirement of $15 million, which poses a risk to its continued listing on the exchange.
- Market Reaction: Despite the compliance issue, Trinity Biotech's stock price rose due to an order for 9 million TrinScreen HIV tests, reflecting market confidence in product demand and potentially alleviating investor concerns regarding compliance deficiencies.
- Rating Dynamics: Seeking Alpha's Quant Rating on Trinity Biotech reveals mixed market sentiment about its future performance; while compliance issues persist, the increase in orders may influence investor perceptions positively.
- Financial Disclosure: Financial information from Trinity Biotech indicates its market performance; despite compliance challenges, the expansion of its product line and growth in orders may provide financial support to help navigate current compliance pressures.
See More
Trinity Biotech Receives Regulatory Approval for New Production Model Launch
- Regulatory Milestone: Trinity Biotech has received local regulatory approval, marking the initiation of upstream manufacturing activities for its Uni-Gold™ HIV rapid test under a new outsourced production model, which is a key component of the company's comprehensive transformation plan.
- Cost Efficiency Improvement: The implementation of the offshore and outsourced production model is expected to significantly enhance gross margins and improve working capital efficiency, thereby strengthening the company's long-term competitiveness in the global HIV rapid testing market.
- Market Demand Support: This transition will not only meet the anticipated growth in demand for Uni-Gold™ HIV products but also provide the necessary scalability to ensure the company remains agile and responsive in a rapidly changing market environment.
- Strategic Transformation Plan: This approval complements the WHO authorization obtained in November 2025, demonstrating the company's strong commitment to executing its comprehensive transformation plan, which is expected to lay a solid foundation for future financial performance.
See More
Indaptus Therapeutics Stock Soars 64.65% to $3.26 After Securities Agreement
- Significant Stock Movement: Indaptus Therapeutics saw its stock decline 2.46% to $1.98 at close but surged 64.65% to $3.26 in after-hours trading, indicating strong investor confidence in its future potential.
- Financing Agreement: The company entered into a securities purchase agreement with investor David E. Lazar on December 22, 2025, selling 1 million shares of convertible preferred stock for $6 million, which is expected to provide financial support pending shareholder approval.
- Positive Market Reaction: Trinity Biotech's stock surged 43.50% to $1.28 after announcing a significant HIV testing order, reflecting market optimism regarding its financial stability and demand recovery.
- Pipeline Restart Approval: Sable Offshore's shares rose 36.32% to $10.36 following the U.S. Pipeline and Hazardous Materials Safety Administration's approval of the Las Flores Pipeline system restart plan, marking a critical step forward in the company's operational recovery.
See More
Dow Jones Index Gains Over 100 Points as Durable Goods Orders Decline 2.2%
- Dow Jones Index Rise: The Dow Jones index increased by over 100 points on Tuesday, closing at 48,469.41, indicating a moderate market recovery despite disappointing economic data.
- Durable Goods Orders Decline: U.S. durable goods orders fell by 2.2% month-over-month to $307.4 billion in October, significantly missing market expectations of a 1.5% decline, reflecting weak manufacturing demand that could impact future economic growth.
- Accelerated GDP Growth: The U.S. GDP grew at an annualized rate of 4.3% in the third quarter, up from 3.8% in the previous quarter and exceeding market estimates of 3.3%, indicating potential for economic recovery that may positively influence the stock market.
- Mixed Sector Performance: Communication services rose by 0.5% while consumer staples fell by 0.5%, demonstrating varied market reactions across sectors, prompting investors to monitor industry dynamics for strategic adjustments.
See More
